Search

Your search keyword '"Vincenzo Di Nunno"' showing total 4 results
Start Over Author "Vincenzo Di Nunno" Journal european urology
4 results on '"Vincenzo Di Nunno"'

1. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?

Author

Vincenzo di Nunno, Karim Bensalah, Louis Leblanc, Sylvain Ladoire, Jochen Walz, Pierre Werle, Pierre Bigot, Gwenaelle Gravis, Philippe Barthélémy, Laurence Albiges, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Géraldine Pignot, L. Balssa, and Hervé Lang

Subjects
business.industry, Urology, Immune checkpoint inhibitors, medicine.medical_treatment, Remission Induction, medicine.disease, Combined Modality Therapy, Nephrectomy, Kidney Neoplasms, Renal cell carcinoma, Cancer research, Medicine, Feasibility Studies, Humans, business, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Complete response, Retrospective Studies
Published
2019

2. Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8

Author

Francesco Massari and Vincenzo Di Nunno

Subjects
medicine.medical_specialty, Carcinoma, Transitional Cell, Urologic Neoplasms, Metastatic Urothelial Carcinoma, business.industry, Urology, Locally advanced, Antibodies, Monoclonal, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Medicine, Humans, 030212 general & internal medicine, business, Platinum
Published
2018

3. Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8

Author

Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni

Subjects
medicine.medical_specialty, business.industry, Sunitinib, Urology, medicine.medical_treatment, medicine.disease, Nephrectomy, Surgery, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, 030220 oncology & carcinogenesis, medicine, Overall survival, 030212 general & internal medicine, business, Adjuvant, medicine.drug
Published
2017

4. Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405–15

Author

Matteo Santoni, Francesco Massari, and Vincenzo Di Nunno

Subjects
Oncology, medicine.medical_specialty, business.industry, Urology, Pembrolizumab, medicine.disease, Axitinib, 03 medical and health sciences, Dose finding, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Monoclonal, medicine, Carcinoma, Cell cancer, In patient, 030212 general & internal medicine, Open label, business, medicine.drug
Published
2018

Catalog

Books, media, physical & digital resources
See catalog results